SCHEMBL4874129

SCHEMBL4874129

CC(NC1=NC(=Cc2c[nH]c3ncc(NC(=O)C4CCN(C)CC4)cc23)C(=O)N1)c1ccccc1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MKNK1 Q9BUB5 1/20 0.38
▸ GSK3B P49841 6/20 0.36
▸ MAPK1 P28482 6/20 0.36
▸ DYRK1A Q13627 4/20 0.36
▸ LIMK2 P53671 3/20 0.35
▸ GSK3A P49840 2/20 0.35
▸ PIP5K1C O60331 1/20 0.35
▸ PIK3CA P42336 1/20 0.35
▸ CSF1R P07333 1/20 0.34
▸ DYRK3 O43781 1/20 0.34
▸ CLK1 P49759 1/20 0.34
▸ CLK2 P49760 1/20 0.34
▸ CLK3 P49761 1/20 0.34
▸ DYRK2 Q92630 1/20 0.34
▸ CLK4 Q9HAZ1 1/20 0.34
▸ DYRK4 Q9NR20 1/20 0.34
▸ DYRK1B Q9Y463 1/20 0.34
▸ BTK Q06187 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4874122 1.00 MKNK1 (0.38) MKNK1GSK3BMAPK1DYRK1ALIMK2
SCHEMBL5095276 0.89 MKNK1 (0.34) MKNK1GSK3BDYRK1ALIMK2GSK3A
SCHEMBL5095275 0.89 MKNK1 (0.34) MKNK1GSK3BDYRK1ALIMK2GSK3A
SCHEMBL5101129 0.87 FLT3 (0.40) MKNK1GSK3BDYRK1AGSK3ACLK1
SCHEMBL5101133 0.87 FLT3 (0.40) MKNK1GSK3BDYRK1AGSK3ACLK1
SCHEMBL5094441 0.86 MKNK1 (0.42) MKNK1GSK3BDYRK1ALIMK2GSK3A
SCHEMBL5094445 0.86 MKNK1 (0.42) MKNK1GSK3BDYRK1ALIMK2GSK3A
SCHEMBL5092772 0.84 DYRK1A (0.49) GSK3BDYRK1ADYRK3CLK1CLK2
SCHEMBL5092770 0.84 DYRK1A (0.49) GSK3BDYRK1ADYRK3CLK1CLK2
SCHEMBL5095374 0.83 DYRK1A (0.37) GSK3BDYRK1ADYRK3CLK1CLK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1960399-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS Pfizer Italia S.r.l. (IT) 2008-08-27 — — EP claimed
US-7371862-B2 Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them PFIZER ITALIA S.R.L. (IT) 2008-05-13 — — US claimed
WO-2007054508-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS PFIZER ITALIA SRL (IT) 2007-05-18 — — WO claimed
US-20070112020-A1 Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them PHARMACIA ITALIA S.P.A. (IT) 2007-05-17 — — US claimed
US-7371862-B2 Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them PFIZER ITALIA S.R.L. (IT) 2008-05-13 — — US disclosed
US-20070112020-A1 Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them PHARMACIA ITALIA S.P.A. (IT) 2007-05-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070112020-A1 Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them MAP3K20, MAP3K6, MAP3K1 MKNK1 68/4885GSK3B 203/4885MAPK1 102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback